Skip to main content
  • Clinical
      |Clinical
    • Acute Coronary Syndromes
    • Cardiac Surgery
    • Covid-19
    • Heart Failure
    • Heart Health
    • Heart Rhythm
    • Hypertension
    • Interventional Cardiology
    • Mitral Valve
    • Pharmaceutics
    • Research
    • Structural Heart Disease
    • TAVR
    • Therapies
    • Tricuspid Valve
    • Vascular & Endovascular
  • Management
      |Management
    • Chest Pain Guidelines
    • Compensation
    • Economics
    • Education & Training
    • Legal News
    • Patient Care
    • Policy & Regulations
    • Professional Associations
    • Quality
    • Revenue
    • Staffing
  • Technology
      |Technology
    • AI
    • Cardiac Imaging
    • Cath Lab
    • CT
    • CVIS
    • ECG
    • Echo
    • EP Lab
    • Informatics
    • MRI
    • Nuclear Cardiology
    • Remote Monitoring
  • Videos
  • Conferences
      |Conferences
    • ACC
    • AHA
    • ASE
    • ASNC
    • ESC
    • EuroPCR
    • HFSA
    • HRS
    • SCAI
    • SCCT
    • SIIM
    • SNMMI
    • STS
    • TCT
    • VIVA
  • Custom Content
      |Custom Content
    • Experience Stories
    • Webinars & Videos
  • Subscribe

Search form

Home
News You Need to Know Today
News Alert: FDA announces a new recall for extended-release metformin due to contamination
Thursday, January 13, 2022
Link to Twitter Link to Facebook Link to Linkedin Link to Vimeo

News Alert

FDA announces a new recall for extended-release metformin due to contamination

The FDA first announced the detection of high levels of NDMA, a contaminant associated with cancer, in extended-release metformin products back in May 2020. 

READ MORE >
medicine-4097308_960_720.jpg
Share on Twitter Share on Facebook Share on Linkedin

FDA announces a new recall for extended-release metformin due to contamination

Share on Twitter Share on Facebook Share on Linkedin
medicine-4097308_960_720.jpg
The FDA first announced the detection of high levels of NDMA, a contaminant associated with cancer, in extended-release metformin products back in May 2020. 
READ MORE >

Innovate Healthcare thanks our partners for supporting our newsletters.
Sponsorship has no influence on editorial content.

Interested in reaching our audiences, contact our team

*|LIST:ADDRESSLINE|*

You received this email because you signed up for newsletters from Innovate Healthcare.
Change your preferences or unsubscribe here

Contact Us  |  Unsubscribe from all  |  Privacy Policy

© Innovate Healthcare, a TriMed Media brand
Innovate Healthcare

Recent Newsletters

TAVR Highlights: Premounted valve saves time | Alternatives to transfemoral access | Surgeon sues hospital
High costs may limit impact of weight loss drug semaglutide | Postoperative delirium after TAVR
August's Top 10 Stories: Multiple recalls | AI-enabled echo | New TAVR valves save time | 'Unfair' policies
AI-enabled echo | Semaglutide & heart failure | Medicare price negotiations | ViV TMVR | More from the last week
FDA shares update on troubled heart devices | Redo TAVR with balloon-expandable valves is safe & effective
Looking back at ESC Congress 2023 | Pre-TAVR CT scans | Weight loss products recalled due to heart risks
Statin use after bleeding strokes | Treating TAVR patients with low-flow, low-gradient AS & severe MR

Pagination

    • First page « First
    • Previous page ‹ Previous
    • Page …20
    • Page 21
    • Page 22
    • Page 23
    • Current page 24
    • Page 25
    • Page 26
    • Page 27
    • Page 28 …
    • Next page Next ›
    • Last page Last »
  • Home
  • News
  • Sitemap
  • Custom Content
  • Webinars
  • Press Releases
  • Content Studio
  • Advertising
  • Submit Press Release
  • Contact Us
  • Terms of Use
  • Privacy Policy
  • AI in Healthcare
  • Cardiovascular Business
  • HealthExec
  • Health Imaging
  • Radiology Business
 
© 2024 Innovate Healthcare | All Rights Reserved. | Terms of Use | Privacy Policy
 
Design by Adaptive Theme